CHICAGO, May 31 (Reuters) - Swiss drugmaker Roche Holding AG’s (ROG.VX: Quote, Profile, Research) oral chemotherapy drug Xeloda, or capecitabine, proved inferior to standard chemotherapy in treating older women with early stage breast cancer, a study released on Saturday at a major meeting of oncology specialists found.
